Syngene International, under the leadership of MD and CEO Peter Bains, has reported a strong start to FY25 with significant revenue growth driven by research services and successful pilot project conversions. The company’s focus on scaling up biologics manufacturing in Bengaluru and expanding operations in the US signals a promising outlook for the future.
While the first quarter results showcased robust momentum, Bains anticipates a moderation in profit after tax (PAT) growth due to depreciation from new facilities. Despite potential headwinds in the biotech industry, Syngene remains optimistic about continued demand for its services and the gradual ramp-up of manufacturing capacities. With a diversified platform catering to a mix of clients, including biotechs, global MNCs, and partners following the China+1 strategy, Syngene is well-positioned to navigate market volatility and capitalize on emerging opportunities.
Read more from thehindubusinessline.com